Nothing said here yet.
to join the conversation.
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup.
The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
Ginkgo Bioworks (NYSE:DNA) reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q2 2026 earnings call